News and Events

August 3, 2017

Title of Blog A

KDL Pathology is committed to high quality, affordable patient care. As such, we are a participating, in-network provider for laboratory and pathology services on all major medical plans. All KDL participating plans may not be listed as they are continually updated– please contact us for questions regarding specific plans.

KDL provides complimentary billing of Medicare and Third Party Insurance and maintains patient-friendly billing policies. Also, please note that KDL, as a participating laboratory network providers, provides the same coverage of patient benefits and deductibles as a providers regardless of designated lab choice.

August 3, 2017

Title of Blog B

KDL Pathology is committed to high quality, affordable patient care. As such, we are a participating, in-network provider for laboratory and pathology services on all major medical plans. All KDL participating plans may not be listed as they are continually updated– please contact us for questions regarding specific plans.

KDL provides complimentary billing of Medicare and Third Party Insurance and maintains patient-friendly billing policies. Also, please note that KDL, as a participating laboratory network providers, provides the same coverage of patient benefits and deductibles as all other lab providers regardless of designated lab choice.

August 3, 2017

Title of Blog C

KDL Pathology is committed to high quality, affordable patient care. As such, we are a participating, in-network provider for laboratory and pathology services on all major medical plans. All KDL participating plans may not be listed as they are continually updated– please contact us for questions regarding specific.

KDL provides complimentary billing of Medicare and Third Party Insurance and maintains patient-friendly billing policies. Also, please note that KDL, as a participating laboratory network providers, provides the same coverage of patient benefits and deductibles as all other lab providers regardless of designated.

July 27, 2017

News 2

Cancer survivors may be at higher risk of developing Melanoma.
July 27, 2017

News 1

FDA approves Erivedge, the first drug to treat advanced basal cell carcinoma.